Vimarsana
Biggest News Aggregation in the World

Frequent Exacerbations News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Frequent Exacerbations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Frequent Exacerbations Today - Breaking & Trending Today

AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio - Vimarsana News

AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio

Published: May 1, 2024

New data for TEZSPIRE and BREZTRI demonstrate AstraZeneca’s innovation and commitment to transform care in COPD ...

Source: marketscreener.com
Related Topics:
San DiegoUnited StatesEast SussexUnited KingdomSharon BarrLymphopoietin IsoformsAmerican Lung AssociationInternational ConferenceGlobal Initiative On Obstructive Lung DiseaseKyowa Kirin Co LtdAmerican Thoracic Society International ConferenceGlobal Asthma NetworkBiowa IncAmerican Partnership For Eosinophilic DisordersNational HeartBlood InstituteCenters For DiseaseGlobal Initiative For Chronic Obstructive Lung DiseaseAmerican Thoracic SocietyExecutive Vice PresidentBiopharmaceuticals Business UnitBayesian Dynamic Borrowing ApproachAlbuterol Budesonide As NeededJanus KinaseBritish Early
FASENRA approved for treatment of children aged 6 to 11 with severe asthma - Vimarsana News

FASENRA approved for treatment of children aged 6 to 11 with severe asthma

Published: April 11, 2024

Additional indication for pediatric patients with severe eosinophilic asthma ...

Source: marketscreener.com
Related Topics:
United KingdomLiz BodinLynda MitchellMinerva PediatrBiowa IncAllergy Asthma NetworkDrug AdministrationWorld Health OrganizationKyowa Kirin Co LtdAsthma NetworkVice PresidentAsthma SymptomsPrescribing InformationPatient InformationRare DiseasesPediatri Allergy ImmunolAllergy ClinZeneca Annual ReportVery Severe Chronic Obstructive Pulmonary DiseaseFrequent ExacerbationsSafety StudyPatients With Hypereosinophilic Syndrome
MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA - Vimarsana News

MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA

Published: February 23, 2024

FASENRA enabled patients to taper off oral corticosteroids while preventing relapses ...

Source: marketscreener.com
Related Topics:
United StatesUnited KingdomSharon BarrMichael WechslerInternational Coordinating InvestigatorBiowa IncKyowa Kirin Co LtdAmerican Academy Of Allergy Asthma ImmunologyAsthma Institute At National Jewish HealthAmerican Partnership For Eosinophilic DisordersNew England JournalAmerican AcademyAllergy AsthmaAnnual MeetingBirmingham Vasculitis Activity ScoreAsthma InstituteNational Jewish HealthExecutive Vice PresidentAsthma SymptomsDeteriorating DiseaseCorticosteroid DosagePrescribing InformationChurg Strauss SyndromeAstrazeneca BiopharmaceuticalsRare Diseases
MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA - Vimarsana News

MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA

Published: February 23, 2024

23.02.2024 - Positive results from the MANDARA Phase III trial for FASENRA (benralizumab) in patients with EGPA were published in the New England Journal of Medicine today,1 as the first head-to-head trial of biologics in patients with EGPA,2 and the first to ...

Source: wallstreet-online.de
Related Topics:
United KingdomUnited StatesMichael WechslerSharon BarrKyowa Kirin Co LtdInternational Coordinating InvestigatorAmerican Partnership For Eosinophilic DisordersBiowa IncAsthma Institute At National Jewish HealthAsthma InstituteNational Jewish HealthExecutive Vice PresidentAsthma SymptomsDeteriorating DiseaseCorticosteroid DosagePrescribing InformationChurg Strauss SyndromeBirmingham Vasculitis Activity ScoreAstrazeneca BiopharmaceuticalsRare DiseasesEosinophilic GranulomatosisBreaking Abstracts PresentedScientific SessionsMeeting FebruaryEur Respir
FASENRA met the primary endpoint in the MANDARA Phase III trial in eosinophilic granulomatosis with polyangiitis (EGPA) - Vimarsana News

FASENRA met the primary endpoint in the MANDARA Phase III trial in eosinophilic granulomatosis with polyangiitis (EGPA)

Published: September 11, 2023

First head-to-head trial of biologics in EGPA, comparing a single monthly injection of FASENRA to three injections per month of mepolizumab ...

Source: marketscreener.com
Related Topics:
United StatesUnited KingdomMichael WechslerSharon BarrKyowa Kirin Co LtdAmerican Partnership For Eosinophilic DisordersBiowa IncPrincipal InvestigatorExecutive Vice PresidentOrphan Drug DesignationAsthma SymptomsDeteriorating DiseaseCorticosteroid DosagePrescribing InformationPatient InformationChurg Strauss SyndromeBirmingham Vasculitis Activity ScoreEosinophilic GranulomatosisEur RespirAllergy ClinVery Severe Chronic Obstructive Pulmonary DiseaseFrequent ExacerbationsSafety StudyPatients With Hypereosinophilic SyndromeZeneca Data